⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DWTX News
Dogwood Therapeutics, Inc. Common Stock
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
globenewswire.com
DWTX
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
globenewswire.com
DWTX
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX
Form 8-K
sec.gov
DWTX
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development
accessnewswire.com
RNAZ
DWTX
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
globenewswire.com
DWTX
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
globenewswire.com
DWTX